NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) and published on April 3, 2020 (the “Prospectus”).
The Supplmentary Prospectus has been prepared since NeuroVive, during the subscription period of the ongoing rights issue of shares (the “Rights Issue”), has entered inte an investment undertaking and has decided upon a directed issue of approximately SEK 20 million to the nordic life science investor Hadean Ventures. Information about the directed issue was published by NeuroVive through a press release on April 22, 2020. The press release is available on the Company’s website (www.neurovive.com).
The Supplementary Prospectus has been prepared in accordance with Article 23 in Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) and has today on April 24, 2020 been approved and registered by the SFSA. The Supplementary Prospectus is a part of the Prospcectus and shall be read together with the Prospcectus in all respects. The Prospectus and the Supplementary Prospectus are available on the Company’s website, www.neurovive.com and on Erik Penser Bank’s website, www.penser.se, and will also be available on the SFSA’s website, www.fi.se.
Investors who, prior to the publication of the Supplementary Prospectus, have notified or otherwise consented to subscribe for shares in the Rights Issue are according to Article 23 in the Prospectus Regulation entitled to withdraw their notification or consent within two working days of the publication of the Supplementary Prospectus, i.e. until April 28, 2020. Withdrawal must be made in writing to Erik Penser Bank, P.O. Box 7405, SE-103 91 Stockholm or via e-mail to email@example.com. Investors who have notified to subscribe for shares trough their bank/trustee should contact their bank/trustee regarding withdrawal. Notification that is not withdrawn within the specified time will remain binding and investors who wish to remain with their subscription of shares do not have to take any measures.
For full terms and other information related to the Rights Issue, please refer to the Prospectus and the Supplementary Prospectus.